From Phenotypic Hit to an Orally Active Preclinical Antiviral: Lessons from Zika Drug Discovery
Phenotypic screening can uncover promising antiviral activity, but turning a hit into a differentiated lead raises some of the hardest questions in drug discovery: What is the molecular target? How does the compound work? And how can those insights guide optimization?
Using a Zika virus program as a case study, this webinar shows how phenotypic screening, target identification, structural biology, medicinal chemistry, DMPK, virology, and pharmacology can be integrated across the discovery process. It also explores how mechanistic and structural insights help move a program from initial phenotypic activity toward increasingly optimized compounds, with broader lessons for flaviviruses and other challenging viral targets.
Designed for medicinal chemists, virologists, structural and molecular biologists, DMPK and pharmacology scientists, drug discovery project leaders and R&D decision makers working in antiviral research.
Join us to gain insights into:
- How phenotypic screening can provide starting points for antiviral discovery and lead to subsequent target and mechanism-of-action studies
- How resistance selection, enzymology, and structural biology were leveraged to identify a novel allosteric binding site and elucidate mechanisms of inhibition resulting in a well-characterized lead
- How structural and mechanistic insights informed medicinal chemistry from hit to the lead compound IRBM-Z-2
- How virology, medicinal chemistry, DMPK, and in vivo pharmacology can be integrated to improve potency, selectivity, pharmacokinetic properties, and biological activity
- What allosteric inhibition strategies may reveal about new drug discovery opportunities across clinically relevant flaviviruses